Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc stock is traded at $80.28, with a volume of 242,410. It is down -7.47% in the last 24 hours and down -15.10% over the past month. Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.